Perspective Therapeutics (CATX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 28/100 (MEDIUM), 58.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 22.29% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
- Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
- Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
- Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says
- Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
- Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
- Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital-Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study. — JMIR Cancer 2026 Oct 13 PMID 42868529
- [Methodological exploration of embedding qualitative and mixed methods research in acupuncture pilot trials from the perspective of complex interventions]. — Zhongguo Zhen Jiu 2026 Oct 12 PMID 42864281
- Worsening heart failure is not a single endpoint: a severity-gradient perspective from digoxin in rheumatic heart disease. — Heart Fail Rev 2026 Oct 10 PMID 42859285
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Perspective Therapeutics.
Full CATX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.